$3.71 Billion is the total value of Perceptive Advisors's 109 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 117.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $365,837,000 | +7.7% | 4,059,900 | +0.9% | 9.86% | +26.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $285,090,000 | -6.2% | 5,875,726 | +1.7% | 7.68% | +10.2% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $258,241,000 | -13.5% | 3,314,606 | +14.3% | 6.96% | +1.5% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $197,369,000 | -26.5% | 24,609,700 | +14.4% | 5.32% | -13.7% |
| ATNX | Buy | ATHENEX INC | $130,594,000 | -30.4% | 10,735,245 | +9.3% | 3.52% | -18.3% |
| AMRN | Buy | AMARIN CORPORATION PLCspons adr new | $115,763,000 | -3.7% | 7,636,079 | +23.1% | 3.12% | +13.0% |
| DOVA | Buy | DOVA PHARMACEUTICALS INC | $103,658,000 | +106.9% | 3,708,705 | +4.4% | 2.79% | +142.9% |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $102,610,000 | -34.1% | 6,433,277 | +7.1% | 2.76% | -22.7% |
| SLDB | Buy | SOLID BIOSCIENCES INC | $69,792,000 | +209.1% | 6,749,803 | +71.9% | 1.88% | +262.9% |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $69,755,000 | – | 3,217,522 | +100.0% | 1.88% | – |
| ZYME | Buy | ZYMEWORKS INC | $59,244,000 | +13.7% | 2,388,890 | +0.8% | 1.60% | +33.4% |
| MYOK | Buy | MYOKARDIA INC | $58,956,000 | +6.8% | 1,130,511 | +2.7% | 1.59% | +25.4% |
| NEPT | Buy | NEPTUNE WELLNESS SOLUTIONS INC | $47,835,000 | +59.6% | 13,436,906 | +51.1% | 1.29% | +87.4% |
| VBIV | Buy | VBI VACCINES INC | $45,951,000 | +86.7% | 45,951,556 | +77.1% | 1.24% | +119.1% |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $34,060,000 | +207.0% | 11,203,881 | +140.3% | 0.92% | +260.0% |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $24,014,000 | -32.1% | 3,253,923 | +3.2% | 0.65% | -20.3% |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $22,454,000 | +29.8% | 597,190 | +40.5% | 0.60% | +52.4% |
| YMAB | New | Y-MABS THERAPEUTICS INC | $22,280,000 | – | 854,940 | +100.0% | 0.60% | – |
| BIO | New | BIO-RAD LABORATORIES INC SHS-A- | $21,628,000 | – | 65,000 | +100.0% | 0.58% | – |
| UROV | Buy | UROVANT SCIENCES LTD | $21,275,000 | +43.4% | 2,246,547 | +19.8% | 0.57% | +68.5% |
| VAPO | Buy | VAPOTHERM INC | $16,709,000 | -48.3% | 1,764,470 | +25.6% | 0.45% | -39.3% |
| AGRX | Buy | AGILE THERAPEUTICS INC | $12,711,000 | +21.7% | 10,726,750 | +27.3% | 0.34% | +42.5% |
| TXG | New | 10X GENOMICS INC | $11,088,000 | – | 220,000 | +100.0% | 0.30% | – |
| SCPEU | New | SC HEALTH CORPunit 99/99/9999 | $10,350,000 | – | 1,000,000 | +100.0% | 0.28% | – |
| ADPT | Buy | ADAPTIVE BIOTECHNOLOGIES COR | $9,116,000 | -33.8% | 295,000 | +3.5% | 0.25% | -22.2% |
| New | TELADOC HEALTH INCnote 1.375% 5/1 | $7,398,000 | – | 5,000,000 | +100.0% | 0.20% | – | |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $6,864,000 | – | 50,000 | +100.0% | 0.18% | – |
| HCAT | New | HEALTH CATALYST INC | $6,674,000 | – | 210,924 | +100.0% | 0.18% | – |
| SIC | New | SELECT INTERIOR CONCEPTS INCcl a | $5,707,000 | – | 440,000 | +100.0% | 0.15% | – |
| PRVB | New | PROVENTION BIO INC | $4,548,000 | – | 666,322 | +100.0% | 0.12% | – |
| CERN | New | CERNER CORP | $4,431,000 | – | 65,000 | +100.0% | 0.12% | – |
| ATEC | New | ALPHATEC HOLDINGS INC | $4,267,000 | – | 850,000 | +100.0% | 0.12% | – |
| FULC | New | FULCRUM THERAPEUTICS INC | $3,984,000 | – | 600,000 | +100.0% | 0.11% | – |
| VERU | Buy | VERU INC | $3,564,000 | +15.8% | 1,650,000 | +14.2% | 0.10% | +35.2% |
| TWST | Buy | TWIST BIOSCIENCE CORP | $3,483,000 | +8.3% | 145,856 | +31.6% | 0.09% | +27.0% |
| BGNE | New | BEIGENE LTDput | $2,698,000 | – | 400,000 | +100.0% | 0.07% | – |
| CORV | New | CORREVIO PHARMA CORP | $2,000,000 | – | 1,000,000 | +100.0% | 0.05% | – |
| XBI | Buy | SPDR SERIES TRUSTput | $1,604,000 | +2191.4% | 900,000 | +350.0% | 0.04% | +2050.0% |
| SGEN | New | SEATTLE GENETICS INC | $1,452,000 | – | 17,000 | +100.0% | 0.04% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INCput | $750,000 | – | 200,000 | +100.0% | 0.02% | – |
| NVCR | New | NOVOCURE LTD | $710,000 | – | 9,489 | +100.0% | 0.02% | – |
| ZYNE | New | ZYNERBA PHARMACEUTICALS INCput | $635,000 | – | 200,000 | +100.0% | 0.02% | – |
| MEDP | New | MEDPACE HLDGS INC | $532,000 | – | 6,328 | +100.0% | 0.01% | – |
| ALLK | New | ALLAKOS INC | $507,000 | – | 6,444 | +100.0% | 0.01% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $526,000 | – | 54,645 | +100.0% | 0.01% | – |
| New | ARQULE INC | $391,000 | – | 54,500 | +100.0% | 0.01% | – | |
| GTHX | New | G1 THERAPEUTICS INC | $358,000 | – | 15,702 | +100.0% | 0.01% | – |
| RARX | New | RA PHARMACEUTICALS INC | $342,000 | – | 14,455 | +100.0% | 0.01% | – |
| MRTX | New | MIRATI THERAPEUTICS INCput | $145,000 | – | 100,000 | +100.0% | 0.00% | – |
| CFMS | New | CONFORMIS INC | $93,000 | – | 50,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-05-01 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.